Teruo Hayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Teruo Hayashi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Michiko Fujimoto
National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health--Cellular Stress Signaling Unit and Cellular Pathobiology Section, Integrative Neuroscience Branch, Baltimore, Maryland 21224, USA
3 shared publications- Tsung-Ping Su
Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, NIH/DHHS, Baltimore, USA
2 shared publications Roman Urfer
M's Science Corporation, Kobe, Japan
1 shared publicationShiro Mita
M's Science Corporation, Kobe, Japan
1 shared publication
Latest Publications
Sigma‐1 receptor chaperones regulate the secretion of brain‐derived neurotrophic factor
The sigma‐1 receptor (Sig‐1R) is a novel endoplasmic reticulum (ER) molecular chaperone that regulates protein folding and degradation. The Sig‐1R activation by agonists is known to improve memory, promote cell survival, and exert an antidepressant‐like action in animals. Cutamesine (SA4503), a selective Sig‐1R ligand, was shown to increase BDNF in the hippocampus of rats. How exactly the intracellular chaperone Sig‐1R or associated ligand causes the increase of BDNF or any other neurotrophins is unknown. We examined here whether the action of Sig‐1Rs may relate to the post‐translational processing and release of BDNF in neuroblastoma cell lines. We used in vitro assays and confirmed that cutamesine possesses the bona fide Sig‐1R agonist property by causing the dissociation of BiP from Sig‐1Rs. The C‐terminus of Sig‐1Rs exerted robust chaperone activity by completely blocking the aggregation of BDNF and GDNF in vitro. Chronic treatment with cutamesine in rat B104 neuroblastoma caused a time‐ and dose‐dependent potentiation of the secretion of BDNF without affecting the mRNA level of BDNF. Cutamesine decreased the intracellular level of pro‐BDNF and mature BDNF whereas increased the extracellular level of mature BDNF. The pulse‐chase experiment indicated that the knockdown of Sig‐1Rs decreased the secreted mature BDNF in B104 cells without affecting the synthesis of BDNF. Our findings indicate that, in contrast to clinically used antidepressants that promote the transcriptional upregulation of BDNF, the Sig‐1R agonist cutamesine potentiates the post‐translational processing of neurotrophins. This unique pharmacological profile may provide a novel therapeutic opportunity for the treatment of neuropsychiatric disorders. Synapse, 2012.
Sigma‐1 receptor chaperones regulate the secretion of brain‐derived neurotrophic factor
The sigma‐1 receptor (Sig‐1R) is a novel endoplasmic reticulum (ER) molecular chaperone that regulates protein folding and degradation. The Sig‐1R activation by agonists is known to improve memory, promote cell survival, and exert an antidepressant‐like action in animals. Cutamesine (SA4503), a selective Sig‐1R ligand, was shown to increase BDNF in the hippocampus of rats. How exactly the intracellular chaperone Sig‐1R or associated ligand causes the increase of BDNF or any other neurotrophins is unknown. We examined here whether the action of Sig‐1Rs may relate to the post‐translational processing and release of BDNF in neuroblastoma cell lines. We used in vitro assays and confirmed that cutamesine possesses the bona fide Sig‐1R agonist property by causing the dissociation of BiP from Sig‐1Rs. The C‐terminus of Sig‐1Rs exerted robust chaperone activity by completely blocking the aggregation of BDNF and GDNF in vitro. Chronic treatment with cutamesine in rat B104 neuroblastoma caused a time‐ and dose‐dependent potentiation of the secretion of BDNF without affecting the mRNA level of BDNF. Cutamesine decreased the intracellular level of pro‐BDNF and mature BDNF whereas increased the extracellular level of mature BDNF. The pulse‐chase experiment indicated that the knockdown of Sig‐1Rs decreased the secreted mature BDNF in B104 cells without affecting the synthesis of BDNF. Our findings indicate that, in contrast to clinically used antidepressants that promote the transcriptional upregulation of BDNF, the Sig‐1R agonist cutamesine potentiates the post‐translational processing of neurotrophins. This unique pharmacological profile may provide a novel therapeutic opportunity for the treatment of neuropsychiatric disorders. Synapse, 2012.
- 1 January 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 417 (1) , 635-639
The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria
- 1 January 2012
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 417 (1) , 635-639
The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria
- 1 April 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 77 (4) , 517-528
Detergent-Resistant Microdomains Determine the Localization of σ-1 Receptors to the Endoplasmic Reticulum-Mitochondria Junction
σ-1 receptors (Sig-1Rs) that bind diverse synthetic and endogenous compounds have been implicated in the pathophysiology of several human diseases such as drug addiction, depression, neurodegenerative disorders, pain-related disorders, and cancer. Sig-1Rs were identified recently as novel ligand-operated molecular chaperones. Although Sig-1Rs are predominantly expressed at endoplasmic reticulum (ER) subdomains apposing mitochondria [i.e., the mitochondria-associated ER membrane (MAM)], they dynamically change the cellular distribution, thus regulating both MAM-specific and plasma membrane proteins. However, what determines the location of Sig-1R at the MAM and how the receptor translocation is initiated is unknown. Here we report that the detergent-resistant membranes (DRMs) play an important role in anchoring Sig-1Rs to the MAM. The MAM, which is highly capable of accumulating ceramides, is enriched with both cholesterol and simple sphingolipids, thus forming Triton X-114-resistant DRMs. Sig-1Rs associate with MAM-derived DRMs but not with those from microsomes. A lipid overlay assay found that solubilized Sig-1Rs preferentially associate with simple sphingolipids such as ceramides. Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER largely decreases Sig-1R at DRMs and causes translocation of Sig-1R from the MAM to ER cisternae. These findings suggest that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the microdomains to anchor Sig-1Rs to the location; thus, it serves to stage Sig-1R at ER-mitochondria junctions.
- 1 April 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 77 (4) , 517-528
Detergent-Resistant Microdomains Determine the Localization of σ-1 Receptors to the Endoplasmic Reticulum-Mitochondria Junction
σ-1 receptors (Sig-1Rs) that bind diverse synthetic and endogenous compounds have been implicated in the pathophysiology of several human diseases such as drug addiction, depression, neurodegenerative disorders, pain-related disorders, and cancer. Sig-1Rs were identified recently as novel ligand-operated molecular chaperones. Although Sig-1Rs are predominantly expressed at endoplasmic reticulum (ER) subdomains apposing mitochondria [i.e., the mitochondria-associated ER membrane (MAM)], they dynamically change the cellular distribution, thus regulating both MAM-specific and plasma membrane proteins. However, what determines the location of Sig-1R at the MAM and how the receptor translocation is initiated is unknown. Here we report that the detergent-resistant membranes (DRMs) play an important role in anchoring Sig-1Rs to the MAM. The MAM, which is highly capable of accumulating ceramides, is enriched with both cholesterol and simple sphingolipids, thus forming Triton X-114-resistant DRMs. Sig-1Rs associate with MAM-derived DRMs but not with those from microsomes. A lipid overlay assay found that solubilized Sig-1Rs preferentially associate with simple sphingolipids such as ceramides. Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER largely decreases Sig-1R at DRMs and causes translocation of Sig-1R from the MAM to ER cisternae. These findings suggest that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the microdomains to anchor Sig-1Rs to the location; thus, it serves to stage Sig-1R at ER-mitochondria junctions.